PCP
REGN icon

Perbak Capital Partners’s Regeneron Pharmaceuticals REGN Stock Holding History

Perbak Capital Partners’s Portfolio REGN Stock Details REGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$931K Buy
1,205
+891
+284% +$682K 0.23% 82
2025
Q4 		$242K Sell
314
-1,665
-84% -$1.13M 0.07% 181
2025
Q3 		$1.11M Buy
1,979
+812
+70% +$459K 0.2% 111
2025
Q2 		$613K Buy
+1,167
New +$651K 0.14% 153
2024
Q3 		– Sell
-650
Closed -$683K – 51
2024
Q2 		$683K Buy
+650
New +$630K 0.2% 54

Other funds holding REGN

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
N
Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return

Perbak Capital Partners's REGN Position: Q1 2026 in Review

Perbak Capital Partners increased its Regeneron Pharmaceuticals (REGN) stake by 284% in Q1 2026, buying an estimated $682K and bringing the position to 1,205 shares worth $931K. The position accounts for 0.23% of the portfolio, ranked #82.

Perbak Capital Partners first reported a position in REGN in Q2 2024 and has held it in 5 quarters since. The position peaked at $1.11M in Q3 2025. 1,392 funds tracked by Wall St. Rank hold REGN as of Q1 2026.

  • Perbak Capital Partners held 1,205 shares of Regeneron Pharmaceuticals worth $931K as of Q1 2026.
  • Perbak Capital Partners bought 891 Regeneron Pharmaceuticals shares in Q1 2026, an estimated $682K.
  • Regeneron Pharmaceuticals made up 0.23% of Perbak Capital Partners's portfolio in Q1 2026, its #82 holding.
  • Perbak Capital Partners first reported a position in Regeneron Pharmaceuticals in Q2 2024 and has held it in 5 quarters since.
  • Perbak Capital Partners's Regeneron Pharmaceuticals position peaked at $1.11M in Q3 2025.
  • 1,392 funds tracked by Wall St. Rank held Regeneron Pharmaceuticals as of Q1 2026.

Based on Perbak Capital Partners's 13F filing for Q1 2026, filed 15 May 2026.